Xenon Pharmaceuticals XENE Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's net change in cash?
- Xenon Pharmaceuticals (XENE) reported net change in cash of $346.7M in Q1 2026.
- How has Xenon Pharmaceuticals's net change in cash changed year-over-year?
- Xenon Pharmaceuticals's net change in cash increased by 1430.7% year-over-year, from -$26.06M to $346.7M.
- What is the long-term trend for Xenon Pharmaceuticals's net change in cash?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's net change in cash has grown at a -25.4% compound annual growth rate (CAGR), from $135.73M to $56.45M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.